Fasciola hepatica infestation in Turkish children

Basit Öğe Kaydı
dc.contributor.authorTokgoz, Yavuz
dc.contributor.authorKarabel, Musemma
dc.contributor.authorBaysoy, Gokhan
dc.contributor.authorGoya, Cemil
dc.contributor.authorCicek, Muttalip
dc.contributor.authorPirinccioglu, Ayfer G.
dc.contributor.authorUluca, Unal
dc.date.accessioned2024-04-24T17:18:48Z
dc.date.available2024-04-24T17:18:48Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND: The data on childhood fascioliasis are limited. We aimed to heighten physicians' awareness of Fasciola Hepatica by presenting 14 cases in this paper. METHODS: The medical records of pediatric patients treated for F. Hepatica infection within the last 2 years were reviewed. ELISA method with a cut-off level of 10 was used as the serological test, in which an absorbance level of >11 DU/mL was considered positive. RESULTS: Ten (71.4%) patients were female. Complaints at presentation were abdominal pain (N.=14; 100%) and loss of appetite (N.=12; 85.7%). Twelve (85.7%) patients were from rural areas. All patients had an elevated eosinophil count (mean: 3885.6/mm(3), minimum: 566/mm(3),maximum: 18687/mm(3)). Six patients had a leucocyte count >10.000 cells/mm(3) and 8 (57%) patients had an ESR>20 mm/h. Gamma-glutamyt transferase (GGT) was normal in all but 1 patient presenting with cholangitis. In hepatobiliary ultrasonography (USG) the most common finding was a heterogeneous solid lesion found in 11 patients. Advanced imaging methods revealed multiple cystic lesions in 10 patients and magnetic resonance imaging (MRI) showed hypo-hyperintense hepatic parenchymal changes in 9 patients. The patients were started on Triclabendazole 10 mg/kg/dose. Clinical, laboratory, and radiological findings of the patients were improved after the therapy. CONCLUSIONS: Fascioliasis should be suspected in children from endemic regions presenting with abdominal pain, weight loss, and fever, which are accompanied by eosinophilia, elevation in transaminases, and cystic/solid lesions in liver, particularly in bile ducts or parenchyma. Triclabendazole is very effective for treatment of this disease.en_US
dc.identifier.doi10.23736/S0393-3660.17.03430-1
dc.identifier.endpage609en_US
dc.identifier.issn0393-3660
dc.identifier.issn1827-1812
dc.identifier.issue11en_US
dc.identifier.scopus2-s2.0-85031294049
dc.identifier.scopusqualityQ4
dc.identifier.startpage603en_US
dc.identifier.urihttps://doi.org/10.23736/S0393-3660.17.03430-1
dc.identifier.urihttps://hdl.handle.net/11468/18913
dc.identifier.volume176en_US
dc.identifier.wosWOS:000415143300008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherEdizioni Minerva Medicaen_US
dc.relation.ispartofGazzetta Medica Italiana Archivio Per Le Scienze Mediche
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFasciola Hepaticaen_US
dc.subjectParasitic Diseasesen_US
dc.subjectChilden_US
dc.titleFasciola hepatica infestation in Turkish childrenen_US
dc.titleFasciola hepatica infestation in Turkish children
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu